Candel Therapeutics, Inc.

TickerCurrent Price% Daily ChangeVolume (1,000s)Average Volumn (1,000s)Market Cap (Millions)1/2/2024 Price% Change Since Inception 1/2/2024
CADL$6.57-9.877%693797$195$1.45353.1%

Contact Information

Candel Therapeutics, Inc.
117 Kendrick Street
Suite 450
Needham, MA 02494
United States

Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at info@candeltx.com.